XOMA Corp (XOMA) Stock: Is It In Your Portfolio Yet?

0

XOMA Corp (NASDAQ: XOMA)

XOMA has become one of my favorite stocks to follow as of late. While the stock has seen its fair share of declines over the past several trading sessions, I’m still relatively bullish. In fact, I believe that after the declines we’ve seen, now is the time to buy. I know, call me crazy, but the catalyst is on its way! Today, we’ll talk about why I believe XOMA is a great stock that will lead to solid gains in the long run.

My Bullish Opinion Revolves Around XOMA 358

When it comes to my bullish opinion, XOMA 358 plays a huge role. XOMA 358 is an experimental treatment that was designed to combat hyperinsulinism. The drug is a fully human allosteric monoclonal antibody and has proven so far to be incredibly effective. So far, there have been two phases of studies on the treatment:

  • Phase 1 – The Phase 1 study of XOMA 358 was designed to prove high tolerability in the treatment. Through the study, XOMA was able to do just that, showing that the the drug was safe and tolerable.
  • Phase 2 – In the Phase 2 study, XOMA set out to prove that the drug was effective while showing more evidence that XOMA 358 was safe. Once again, the company accomplished the mission. In the Phase 2 study, XOMA was able to show that the treatment was effective in reducing hypoglycemia.

After the overwhelmingly positive data from the Phase 1 and Phase 2 studies of XOMA 358, the company is now getting prepared to conduct the Phase 3 study. Given the results from Phase 1 and Phase 2, there’s no reason to expect that Phase 3 isn’t going to end in a positive way. So, I’m expecting to see good news from the study and an NDA filed with the FDA relatively soon.

XOMA Has An Incredible Pipeline

Although it would be quite disheartening if something went wrong with XOMA 358, it wouldn’t be the end of the world for the company. After all, XOMA has an incredible pipeline of candidates. So far, XOMA has 6 candidates that have made it past the pre-clinical phase and are now in clinical trials. They also have 2 candidates that are in pre-clinical trials. The drugs that the company is currently working on are designed to combat hyperinsulinism, enact the reversal of insulin, fight hyperprolactinemias, and far more! All of which are needed treatments in the medical space.

What We Can Expect To See Moving Forward

In the short term, we’re going to see ups and we’re going to see downs, that’s simply the nature of stocks. However, in the long run, I believe that the movement will average out in a positive way. With XOMA 358 doing so well in clinical trials, it’s only a matter of time before the drug becomes FDA approved and is put on the shelves. However, XOMA isn’t likely to stop with XOMA 358. With such an incredible pipeline, I’m expecting to see quite a bit of good news out of the company moving forward. So, if you’re looking for a solid opportunity in the biotech space, you may want to take a close look at XOMA.

What Do You Think?

Where do you think XOMA is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

 

Trade With A CNA Finance Trusted Broker
Broker Trade Fees Promotion Sign Up Here
TradeKing $4.95
Firstrade $6.95
TradeStation $9.99 Open a TradeStation Account!
Previous articleMannKind (MNKD) Stock: “I’m Still A Bull!”
Next articleSunEdison (SUNE) Stock: Can Vivint Solar Save This Stock?
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at CNAFinanceHelp@gmail.com Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.

LEAVE A REPLY

Please enter your comment!
Please enter your name here